Chronic Heart Failure – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chronic Heart Failure – Pipeline Review, H2 2016’, provides an overview of the Chronic Heart Failure pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Heart Failure and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure

The report reviews pipeline therapeutics for Chronic Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Heart Failure therapeutics and enlists all their major and minor projects

The report assesses Chronic Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Heart Failure

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc.

AnGes MG, Inc.

AstraZeneca Plc

Bayer AG

Capricor Therapeutics, Inc.

Celyad SA

Juventas Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Les Laboratoires Servier SAS

Mast Therapeutics, Inc.

Mesoblast Limited

Novartis AG

Pfizer Inc.

scPharmaceuticals Inc

Stemedica Cell Technologies, Inc.

Theravance Biopharma, Inc.

Vichem Chemie Research Ltd.

Zensun (Shanghai) Sci & Tech Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Introduction 9

Global Markets Direct Report Coverage 9

Chronic Heart Failure Overview 10

Therapeutics Development 11

Pipeline Products for Chronic Heart Failure - Overview 11

Pipeline Products for Chronic Heart Failure - Comparative Analysis 12

Chronic Heart Failure - Therapeutics under Development by Companies 13

Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes 15

Chronic Heart Failure - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Chronic Heart Failure - Products under Development by Companies 19

Chronic Heart Failure - Products under Investigation by Universities/Institutes 20

Chronic Heart Failure - Companies Involved in Therapeutics Development 21

Amgen Inc. 21

AnGes MG, Inc. 22

AstraZeneca Plc 23

Bayer AG 24

Capricor Therapeutics, Inc. 25

Celyad SA 26

Juventas Therapeutics, Inc. 27

Laboratoires Pierre Fabre SA 28

Les Laboratoires Servier SAS 29

Mast Therapeutics, Inc. 30

Mesoblast Limited 31

Novartis AG 32

Pfizer Inc. 33

scPharmaceuticals Inc 34

Stemedica Cell Technologies, Inc. 35

Theravance Biopharma, Inc. 36

Vichem Chemie Research Ltd. 37

Zensun (Shanghai) Sci & Tech Co., Ltd. 38

Chronic Heart Failure - Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Combination Products 40

Assessment by Target 41

Assessment by Mechanism of Action 43

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 49

(sacubitril + valsartan) - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

beperminogene perplasmid - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

C3BSCQR-1 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

cenderitide - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

CLR-325 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

dapagliflozin propanediol - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

F-373280 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

furosemide - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

ivabradine hydrochloride - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

JVS-100 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

L-2286 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

MPC-150IM - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

neladenoson bialanate - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Neucardin - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

omecamtiv mecarbil MR - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

rivaroxaban - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

S-38844 - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

serelaxin - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

sildenafil citrate - Drug Profile 123

Product Description 123

Mechanism Of Action 123

R&D Progress 123

Small Molecules for Chronic Heart Failure - Drug Profile 125

Product Description 125

Mechanism Of Action 125

R&D Progress 125

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 126

Product Description 126

Mechanism Of Action 126

R&D Progress 126

Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 132

Product Description 132

Mechanism Of Action 132

R&D Progress 132

TD-1439 - Drug Profile 133

Product Description 133

Mechanism Of Action 133

R&D Progress 133

vepoloxamer - Drug Profile 134

Product Description 134

Mechanism Of Action 134

R&D Progress 134

vericiguat - Drug Profile 142

Product Description 142

Mechanism Of Action 142

R&D Progress 142

Chronic Heart Failure - Dormant Projects 143

Chronic Heart Failure - Discontinued Products 145

Chronic Heart Failure - Product Development Milestones 146

Featured News & Press Releases 146

Sep 19, 2016: Important new analysis shows that Novartis Entresto is associated with higher relative health-related quality of life scores among HFrEF patients 146

Sep 19, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting 147

Sep 12, 2016: AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure 148

Sep 09, 2016: Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting 148

Sep 01, 2016: Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development 149

Aug 28, 2016: CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications 149

Jul 01, 2016: Mesoblast Provides Update On Heart Failure Trial And Funding Of Clinical Operations 151

Jun 28, 2016: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy 152

Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology 153

Jun 14, 2016: Mesoblast Provides Update On Global Heart Failure Program 154

May 23, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress 155

May 23, 2016: Results of Vepoloxamer Nonclinical Studies in Advanced Heart Failure Presented at European Society of Cardiology 3rd World Congress on Acute Heart Failure 155

May 13, 2016: Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016 156

Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition 157

Apr 26, 2016: Celyad receives certification for C-Cure non-clinical data from the European Medicines Agency 158

Appendix 159

Methodology 159

Coverage 159

Secondary Research 159

Primary Research 159

Expert Panel Validation 159

Contact Us 159

Disclaimer 160

List of Tables

List of Tables

Number of Products under Development for Chronic Heart Failure, H2 2016 11

Number of Products under Development for Chronic Heart Failure – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Investigation by Universities/Institutes, H2 2016 20

Chronic Heart Failure – Pipeline by Amgen Inc., H2 2016 21

Chronic Heart Failure – Pipeline by AnGes MG, Inc., H2 2016 22

Chronic Heart Failure – Pipeline by AstraZeneca Plc, H2 2016 23

Chronic Heart Failure – Pipeline by Bayer AG, H2 2016 24

Chronic Heart Failure – Pipeline by Capricor Therapeutics, Inc., H2 2016 25

Chronic Heart Failure – Pipeline by Celyad SA, H2 2016 26

Chronic Heart Failure – Pipeline by Juventas Therapeutics, Inc., H2 2016 27

Chronic Heart Failure – Pipeline by Laboratoires Pierre Fabre SA, H2 2016 28

Chronic Heart Failure – Pipeline by Les Laboratoires Servier SAS, H2 2016 29

Chronic Heart Failure – Pipeline by Mast Therapeutics, Inc., H2 2016 30

Chronic Heart Failure – Pipeline by Mesoblast Limited, H2 2016 31

Chronic Heart Failure – Pipeline by Novartis AG, H2 2016 32

Chronic Heart Failure – Pipeline by Pfizer Inc., H2 2016 33

Chronic Heart Failure – Pipeline by scPharmaceuticals Inc, H2 2016 34

Chronic Heart Failure – Pipeline by Stemedica Cell Technologies, Inc., H2 2016 35

Chronic Heart Failure – Pipeline by Theravance Biopharma, Inc., H2 2016 36

Chronic Heart Failure – Pipeline by Vichem Chemie Research Ltd., H2 2016 37

Chronic Heart Failure – Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016 38

Assessment by Monotherapy Products, H2 2016 39

Assessment by Combination Products, H2 2016 40

Number of Products by Stage and Target, H2 2016 42

Number of Products by Stage and Mechanism of Action, H2 2016 44

Number of Products by Stage and Route of Administration, H2 2016 46

Number of Products by Stage and Molecule Type, H2 2016 48

Chronic Heart Failure – Dormant Projects, H2 2016 143

Chronic Heart Failure – Dormant Projects (Contd..1), H2 2016 144

Chronic Heart Failure – Discontinued Products, H2 2016 145

List of Figures

List of Figures

Number of Products under Development for Chronic Heart Failure, H2 2016 11

Number of Products under Development for Chronic Heart Failure – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 39

Number of Products by Top 10 Targets, H2 2016 41

Number of Products by Stage and Top 10 Targets, H2 2016 41

Number of Products by Top 10 Mechanism of Actions, H2 2016 43

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 43

Number of Products by Routes of Administration, H2 2016 45

Number of Products by Stage and Routes of Administration, H2 2016 45

Number of Products by Molecule Types, H2 2016 47

Number of Products by Stage and Molecule Types, H2 2016 47

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports